Trials / Completed
CompletedNCT04706741
A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis
A Phase 2 Trial of the Efficacy and Safety of the Interleukin-17A Inhibitor Izokibep (ABY-035) in the Treatment of Non-infectious Intermediate, Posterior or Pan-uveitis (LINNAEA)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- ACELYRIN Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at BL despite treatment with stable doses of corticosteroids (≥7 to ≤40 mg/day oral prednisolon or equivalent).
Detailed description
This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at BL despite treatment with stable doses of corticosteroids (≥7 to ≤40 mg/day oral prednisolon or equivalent).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Izokibep | Izokibep is an Interleukin-17 Inhibitor that will be administered subcutaneously |
| DRUG | Prednisone/Prednisolone | Background Corticosteroid |
Timeline
- Start date
- 2022-01-06
- Primary completion
- 2022-08-25
- Completion
- 2022-11-14
- First posted
- 2021-01-13
- Last updated
- 2024-02-12
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04706741. Inclusion in this directory is not an endorsement.